A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Interventions: OTHER: Alpelisib|OTHER: Fulvestrant
Sponsor: Novartis Pharmaceuticals